BISPSMA Trademark

Pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for the treatment of cancers; pharmaceutical preparations and substances for diagnosis of cancers; pharmaceutical preparations and substances for therapy and treatment of cancers; pharmaceutical, medicinal, veterinary and therapeutic preparations and substances for theranostics being the use of radioisotopes for the diagnosis and treatment of cancers; pharmaceutical preparations and substances for facilitating the delivery of pharmaceutical and medicinal preparations and substances, namely, drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; radiopharmaceutical preparations for the treatment and diagnosis of cancers; radioprotectors, namely, drugs or compounds that reduce damage to healthy tissue caused by radiation in the course of the diagnosis and treatment of cancers; radiopharmaceuticals for use in theranostics, namely, imaging and detection agents for diagnosing and treating cancers; radiopharmaceutical products, namely, diagnostic and therapeutic radiopharmaceutical agents for use in PET imaging; radiopharmaceutical diagnostic and therapeutic preparations for medical purposes, namely, radiopharmaceuticals for medical and clinical use; radiopharmaceutical preparations and substances for use in oncology, namely radiopharmaceutical preparations for diagnosing and treating cancer; radiopharmaceutical preparations for the treatment of cancer; radio therapeutic preparations, namely, radio-isotope markers for therapeutic or diagnostic use; chemical substances and preparations being radioactive substances for medical purposes; radioisotopes for medical purposes, namely, radio-isotope markers for therapeutic or diagnostic use; diagnostic and therapeutic radioisotopes and radiochemical preparations for medical purposes, namely, for the treatment of cancers; radiopharmaceutical preparations and substances for endoradionuclide therapy, brachytherapy; radiopharmaceuticals used in the field of nuclear medicine, medical imaging and therapy, namely diagnostic radiopharmaceutical agent for use in PET imaging; diagnostic radiopharmaceutical preparations and substances for positron emission tomography; diagnostic radiopharmaceutical preparations and substances for single photon emission tomography, target radionuclide and peptide receptor radionuclide therapy; pharmaceutical preparations in the field of oncology, namely, theranostics drugs for use in the treatment of cancer; pharmaceutical preparations in the field of precision oncology, namely, theranostics drugs for use in the treatment of cancer; radiopharmaceutical preparations for use in oncology, namely, radiopharmaceutical preparations containing radioisotopes for treatment and diagnosis of tumors; target radiopharmaceutical pharmaceuticals containing a target molecule for the treatment of cancers; pharmaceutical preparations for targeted radionuclide therapy; therapeutic agents for delivery of radioactive material to target sites within the body; irradiated or radioactive microspheres used for therapeutic medical purposes; radiopharmaceutical preparations for use in the imaging, diagnosis and therapy of cancer, osteosarcoma, bone metastases, prostate cancer, breast cancer, brain cancer, ovarian cancer, lung cancer, testicular cancer, renal cancer, bladder cancer, kidney or renal cancer, fallopian tube cancer, uterine leiomyoma, non-Hodgkin's lymphoma, colon cancer, lipoma, basal cell skin carcinoma, squamous cell skin carcinoma, acute myelogenous leukemia, pancreatic cancer, central nervous system cancer, retinoblastoma, neuroblastoma, glioblastoma, Kaposi's sarcoma, Ewing's sarcoma, rhabdomyosarcoma, hermangioma, solid tumors, blood-borne tumors, leukemia and melanoma; radiopharmaceutical preparations containing radioisotopes with short half-lives for diagnostic applications; chemical preparations for pharmaceutical use, namely, for the diagnosis and treatment of cancers; chemical preparations in the nature of radiopharmaceuticals for diagnostic uses; pharmaceutical preparations for the diagnosis of cancers; pharmaceutical preparations for the treatment of cancer; radiopharmaceuticals for use with highly sensitive molecular imaging technologies such as positron emission tomography or single photon emission tomography, for the production of images of organs and lesions and for the early diagnosis of diseases; radiopharmaceutical preparations containing medical radioisotopes with longer half-lives, for the treatment of tumour diseases; chemical preparations for radiopharmaceuticals for diagnostic uses; radiopharmaceutical drugs for diagnostic uses; radiopharmaceutical preparations for diagnostic uses; radio-isotope markers, isotopes, preparations and reagents for medical purposes for use in radioactive labelling of cancer cells; radioactive pharmaceuticals and non-radioactive reagents for producing radiopharmaceuticals for diagnosis or for therapeutic use; diagnostic agents, preparations and substances for medical purposes; diagnostic scanning agents for medical use, namely, diagnostic scanning agents for in vivo use; positron emission tomography tracers for medical use, namely, radioactive isotopes used to label cancer cells; positron emission tomography tracers prepared for ingestion or injection into humans and animals, namely, radioactive isotopes used to label cancer cells; reagents for medical purposes; preparations for use in molecular imaging for medical use, namely, radioactive isotopes for in vivo imaging; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiotherapeutic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; Pharmaceutical preparations and diagnostic preparations for medical purposes, namely, radiodiagnostic preparations used in the application of radioisotopes and radiation in medicine, including nuclear medical diagnostics and therapy, oncologic diagnostics and therapy, hematologic diagnostics and therapy, radiologic diagnostics and therapy; radiopharmaceutical diagnostic preparations for medical use; radiopharmaceutical diagnostic preparations for use in the diagnosis of disease; radioactive marked substances for diagnostic purposes, namely, radio-isotope markers; diagnostic radiopharmaceutical preparations and radio-isotope markers for therapeutic purposes; pharmaceutical solutions for radioactive labelling; diagnostic preparations and reagents for medical use; diagnostic substances for medical use; contrasting substances in the nature of contrasting agents for medical imaging; diagnostic scanning reagents; diagnostic imaging agents for magnetic resonance imaging; diagnostic and therapeutic chemical preparations and reagents for medical purposes